Expert Interview
Exploring Merck Pharmaceuticals data for vibostolimab coformulated with pembrolizumab (vibo/pembro) for treatment of advanced mismatch repair–deficient (dMMR) endometrial cancer presented ASCO 2024
Ticker(s): MRKInstitution: University of Leuven
- Emeritus Professor with Scientific assignment at the Catholic University of Leuven and consultant at the University Hospitals Leuven
- Main areas of clinical and translational research focus on gynecological cancer. He has authored more than 1020 original full papers in peer-reviewed journals.
- Currently Editor of the European Journal of Cancer
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
